Pharmaceuticals company Piramal Pharma announced Q1FY26 results Revenue from Operations stood at Rs 1,934 crore vs Rs 1,951 crore in Q1FY25. Excluding the impact of destocking in one of the large CDMO product, the YoY revenue growth was in early double-digit EBITDA margin at 9% vs 11% in Q1FY25. Impact of inventory destocking, partly offset by improved profitability of the overseas facilities in the CDMO business Net-Debt to EBITDA ratio at 2.6x Best-in-Class Quality Track Record – Successfully closed USFDA inspection at Aurora facility (Canada) with zero observations. Continue to maintain our ‘Zero OAIs’ status since 2011 Sustainability Efforts Yielding Results – Assigned an ESG rating of ‘61’ for FY2024 by NSE Sustainability Ratings and Analytics Limited Nandini Piramal, Chairperson, Piramal Pharma said, “Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in-line with our expectations, driven by power brands and ecommerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE.” Result PDF
Conference Call with Piramal Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Piramal Pharma announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations for Q4FY25 was Rs 2,754 crore, an increase of 8% compared to Rs 2,552 crore in Q4FY24. EBITDA grew by 8% YoY and 15% YoY in Q4FY25 and FY25 respectively, on account of operating leverage, cost optimization, and operational excellence initiatives EBITDA for Q4FY25 was Rs 603 crore, an increase of 8% compared to Rs 556 crore in Q4FY24. The EBITDA Margin was 22% in both Q4FY25 and Q4FY24. PAT (before exceptional item) for Q4FY25 was Rs 154 crore, an increase of 16% compared to Rs 132 crore in Q4FY24. PAT (after exceptional item) for Q4FY25 was Rs 154 crore, a significant increase of 52% compared to Rs 101 crore in Q4FY24. FY25 Financial Highlights: Revenue from Operations for FY25 was Rs 9,151 crore, an increase of 12% compared to Rs 8,171 crore in FY24. EBITDA for FY25 was Rs 1,580 crore, an increase of 15% compared to Rs 1,372 crore in FY24. The EBITDA Margin was 17% in both FY25 and FY24. PAT (before exceptional item) for FY25 was Rs 91 crore, an increase of 13% compared to Rs 81 crore in FY24. PAT (after exceptional item) for FY25 was Rs 91 crore, a substantial increase of 411% compared to Rs 18 crore in FY24. Nandini Piramal, Chairperson, Piramal Pharma said, “FY25 has been a steady year for the company as we crossed USD 1 billion in revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our key performance metrics such as growth in innovation related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business. We believe, we are on track to deliver on our FY2030 aspirations of becoming a USD 2 billion revenue company with 25% EBITDA margins and high teens ROCE.” Result PDF